NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Rezolute, Inc. (RZLT) Stock Analysis

Rezolute, Inc. (RZLT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

RZLT

$4.58

+$0.04 (+0.88%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RZLT with… →

RZLT Key Statistics

As of Sep 4, 2026
Trading
Open
$4.49
Previous Close
$4.54
Day's Range
4.44–4.62
52-Week Range
1.07–11.46
Volume
716.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.61
Valuation
Market Cap
$441.02M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.82
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$74.41M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
96.29M
1-Year Return
−37.94%
Dividend and dates
Earnings Date
September 16, 2026estimated
Avg Volume
1.68M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RZLT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+94.07%
2025−51.84%
2024+393.45%
2023−52.03%
2022−56.69%
2021−60.13%
2020+108.52%
2019+27.78%
2018−89.83%
2017−11.50%
2016 (partial year)+16.96%

As of September 4, 2026.

RZLT Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$74.41M—
2024$0.00−$68.46M—
2023$0.00−$51.79M—
2022$0.00−$41.06M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$79.89M−$74.41M—
2024$0.00—−$70.42M−$68.46M—
2023$0.00—−$55.99M−$51.79M—
2022$0.00—−$41.61M−$41.06M—

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

RZLT Valuation vs Biotechnology Median

Median of 656 stocks
MetricRZLTBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Rezolute, Inc. (RZLT) is capitalised at $441.02M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 68 employees.

RZLT last closed at $4.58 on September 4, 2026. That is +$0.04 (+0.88%) against the previous close. The 52-week range on file runs from $1.07 to $11.46. The latest close sits 328.04% above that 52-week low.

Financial Health

In fiscal 2025, Rezolute, Inc. reported revenue of $0.00. The same year closed with a net loss of $74.41M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.82.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is −37.94%. Across 10 years the annualized return works out at −21.02%. The reported beta is 0.61. Daily returns over the trailing 10 years annualize to a volatility of 159.95%.

Growth & Income

The record shows no dividend for RZLT.

So far in 2026 the price is +94.07%. Across the complete calendar years on file, 2024 returned +393.45% and 2018 returned −89.83%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Rezolute, Inc. (RZLT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Rezolute, Inc. RZLT $441.02M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Rezolute, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Rezolute, Inc.

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Visit website →